GSK raises 2024 core EPS growth view to 8%-10% from 6%-9%

Now expects 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% previously 7% to 10%. Dividend declared of 15p for Q1 2024; 60p expected for 2024.